Equities analysts predict that Allscripts (NASDAQ:MDRX) will post $0.18 earnings per share (EPS) for the current fiscal quarter, Zacks reports. Ten analysts have issued estimates for Allscripts’ earnings. The lowest EPS estimate is $0.17 and the highest is $0.20. Allscripts posted earnings per share of $0.15 in the same quarter last year, which would suggest a positive year over year growth rate of 20%. The firm is expected to issue its next quarterly earnings results on Thursday, August 2nd.
On average, analysts expect that Allscripts will report full-year earnings of $0.77 per share for the current year, with EPS estimates ranging from $0.74 to $0.80. For the next year, analysts forecast that the business will report earnings of $0.88 per share, with EPS estimates ranging from $0.82 to $0.97. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that cover Allscripts.
Allscripts (NASDAQ:MDRX) last issued its earnings results on Thursday, May 3rd. The software maker reported $0.16 EPS for the quarter, missing analysts’ consensus estimates of $0.17 by ($0.01). Allscripts had a positive return on equity of 7.80% and a negative net margin of 11.34%. The firm had revenue of $518.60 million for the quarter, compared to analysts’ expectations of $527.34 million. During the same period last year, the firm earned $0.13 earnings per share. Allscripts’s revenue for the quarter was up 24.9% on a year-over-year basis.
MDRX has been the topic of a number of analyst reports. TheStreet raised shares of Allscripts from a “c” rating to a “b-” rating in a research note on Thursday, February 15th. Cantor Fitzgerald reissued a “buy” rating and issued a $18.00 price target on shares of Allscripts in a research note on Thursday, April 5th. Bank of America assumed coverage on shares of Allscripts in a research note on Tuesday, February 27th. They issued a “buy” rating and a $17.00 price target on the stock. Wells Fargo set a $19.00 price target on shares of Allscripts and gave the company a “buy” rating in a research note on Saturday, February 17th. Finally, BidaskClub raised shares of Allscripts from a “hold” rating to a “buy” rating in a research note on Friday, February 16th. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating and thirteen have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $16.01.
Allscripts traded down $0.32, reaching $12.54, during trading on Monday, Marketbeat.com reports. 92,389 shares of the stock were exchanged, compared to its average volume of 2,037,744. The company has a debt-to-equity ratio of 1.53, a current ratio of 1.02 and a quick ratio of 1.02. Allscripts has a 1 year low of $10.78 and a 1 year high of $16.13. The company has a market capitalization of $2.29 billion, a PE ratio of 26.66, a price-to-earnings-growth ratio of 1.70 and a beta of 1.24.
In other news, EVP Brian Farley sold 5,000 shares of the company’s stock in a transaction on Wednesday, March 14th. The shares were sold at an average price of $13.73, for a total value of $68,650.00. Following the completion of the transaction, the executive vice president now owns 240,672 shares in the company, valued at approximately $3,304,426.56. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, President Richard J. Poulton sold 15,000 shares of the company’s stock in a transaction on Thursday, March 15th. The shares were sold at an average price of $13.53, for a total transaction of $202,950.00. Following the completion of the transaction, the president now owns 505,920 shares of the company’s stock, valued at approximately $6,845,097.60. The disclosure for this sale can be found here. Insiders own 1.10% of the company’s stock.
A number of hedge funds have recently added to or reduced their stakes in MDRX. Oakbrook Investments LLC purchased a new stake in Allscripts in the 4th quarter valued at $194,000. First Quadrant L P CA raised its position in Allscripts by 22.7% in the 4th quarter. First Quadrant L P CA now owns 76,447 shares of the software maker’s stock valued at $1,112,000 after purchasing an additional 14,147 shares during the last quarter. Fisher Asset Management LLC raised its position in Allscripts by 1.8% in the 4th quarter. Fisher Asset Management LLC now owns 2,386,237 shares of the software maker’s stock valued at $34,720,000 after purchasing an additional 42,504 shares during the last quarter. Boston Advisors LLC raised its position in Allscripts by 25.8% during the 4th quarter. Boston Advisors LLC now owns 573,037 shares of the software maker’s stock worth $8,338,000 after buying an additional 117,615 shares during the last quarter. Finally, SG Americas Securities LLC raised its position in Allscripts by 41.0% during the 4th quarter. SG Americas Securities LLC now owns 71,380 shares of the software maker’s stock worth $1,039,000 after buying an additional 20,746 shares during the last quarter.
Allscripts Company Profile
Allscripts Healthcare Solutions, Inc provides information technology solutions and services to healthcare organizations in the United States, Canada, and internationally. It offers electronic health records, connectivity, private cloud hosting, outsourcing, analytics, patient engagement, clinical decision support, and population health management solutions.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Allscripts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allscripts and related companies with MarketBeat.com's FREE daily email newsletter.